Phase 1b/2 Study: Ivosidenib, Durvalumab, & Gemcitabine/Cisplatin in IDH1-Mutant Cholangiocarcinoma

Institut de Recherches Internationales Servier is evaluating the safety, tolerability, and preliminary clinical activity of a combination therapy—ivosidenib with durvalumab and gemcitabine/cisplatin—as first-line treatment in patients with advanced, unresectable or metastatic cholangiocarcinoma harboring an IDH1 mutation, starting with a safety lead-in phase followed by an expansion phase.